Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

Role of PCSK9 Inhibitors in Diabetes

Stephen Kopecky

New Insights into Triglyceride Therapy and the Role of Omega-3 Fatty…

National Lipid Association

R. Mason

Obesity and Diabetes in Children

Ilene Fennoy

Medications for Weight Loss: The New Satiety Hormones

Scripps Health

K. Fujioka

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

University of Colorado Department of Medicine

R. Johnson

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

Labs to Check on Semaglutide or Tirzepatide

Susan Brian

Weightloss in Menopause

Susan Brian

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

Northwestern Medicine: The Connection Between Diabetes and Heart Dis…

Northwestern Medicine Bluhm Cardiovascular Institute

S. Shah, R. Kushner

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a Safer…

Ken Fujioka

Tirzepatide Updates

Diana Isaacs

Effects of Low Calorie and Alternative Sweeteners Across the Lifespa…

Keck School of Medicine of USC

M. Goran

Colchicine: Now and What’s Next?

National Lipid Association

C. Ballantyne

The Differences Between the Products of GLP1's and GLP/GIPs

Susan Brian